Bronchogen
- Category
- Bioregulators
- Administration routes
- InjectableOral
- Regulatory status
- Not FDA-approved
What it is
Bronchogen is a short synthetic peptide marketed to repair bronchial cells and support airway gene regulation and mucus balance. Evidence is thin: benefits are low-confidence, based mainly on animal and mechanism-level work by one Russian group with no independent replication or human trials. The key gap is safety, with no established human safety profile or bioavailability data. It is not FDA-approved and sold only as an unregulated research compound.
Read Full recordStudied uses & evidence
Studied uses(8)
Bronchial epithelial restoration
LowReversed epithelial damage in a rat COPD model and in vitro, no human trials yet.
Anti-inflammatory (respiratory)
LowReduced inflammatory markers and cell infiltration in a single rat COPD study.
Local immune defense enhancement
SpeculativeIncreased secretory IgA in one rat study, without any infection-clearance testing.
Evidence limits
- Evidence Level
- Preclinical
All evidence derives from in vitro cell culture studies (human bronchial epithelial cell lines) and in vivo rat models (NO2-induced COPD). Research spans approximately 2006-2022 and originates almost entirely from Russian institutions affiliated with V.Kh. Khavinson. No independent replication by non-Russian research groups. No randomized controlled human trials. Evidence is promising but limited and lacks independent verification.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(9)
Risks = level of concern: High · Moderate · Low · Theoretical
No human clinical trials — safety and efficacy in humans unestablished
HighAlmost all research from single Russian research group (Khavinson) — no independent Western replication
ModerateTheoretical concern: gene expression modulation (NKX2-1, FOXA1/2) could affect pre-existing lung malignancies
TheoreticalPotential immune enhancement via sIgA upregulation may be contraindicated in autoimmune lung conditions
TheoreticalLong-term effects of chronic DNA-binding peptide administration unknown
TheoreticalOral bioavailability not rigorously characterized in peer-reviewed studies
ModerateQuality varies significantly among unregulated products sold online — no pharmaceutical-grade manufacturing standards
ModeratePregnancy and lactation safety data absent
ModerateInteractions with bronchodilators, corticosteroids, and immunosuppressants unstudied
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.